Forbes
@forbes·2.1M subscribers·11.3K videos
This Pharma Company Is Betting Big On A Chinese Ozempic Rival
Posted
April 15, 2025
Views
7,781
Likes
134
Comments
11
Engagement
1.86%
April 15, 2025
7,781
134
11
1.86%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
5:16Now PlayingKailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center.
Read the full story on Forbes
Subscribe to FORBES
Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news, groundbreaking in-depth reported stories, daily digests and more. Plus, members get a front-row seat at members-only events with leading thinkers and doers, access to premium video that can help you get ahead, an ad-light experience, early access to select products including NFT drops and more:
Stay Connected
Forbes newsletters
Forbes on Facebook
Forbes Video on Twitter
Forbes Video on Instagram
More From Forbes
Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
